Base de dados : MEDLINE
Pesquisa : D27.505.519.562.061 [Categoria DeCS]
Referências encontradas : 278 [refinar]
Mostrando: 1 .. 10   no formato [Detalhado]

página 1 de 28 ir para página                         

  1 / 278 MEDLINE  
              next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28388719
[Au] Autor:Kane MA; Monheit G
[Ad] Endereço:Plastic surgeon in private practice in New York, NY, USA.
[Ti] Título:The Practical Use of AbobotulinumtoxinA in Aesthetics.
[So] Source:Aesthet Surg J;37(suppl_1):S12-S19, 2017 05 01.
[Is] ISSN:1527-330X
[Cp] País de publicação:England
[La] Idioma:eng
[Ab] Resumo:Botulinum toxin (BoNT) has been approved for aesthetic use since 2002. Since then, clinical studies and expert use have informed our understanding of how BoNT exerts its clinical effect and the practical use of this product across a number of aesthetic applications. This review discusses the clinical properties and characteristics of abobotulinumtoxinA, which patients are suitable for its use, and how it can be utilized to treat facial rhytides.
[Mh] Termos MeSH primário: Inibidores da Liberação da Acetilcolina/farmacologia
Toxinas Botulínicas Tipo A/farmacologia
Técnicas Cosméticas
Face/anatomia & histologia
Seleção de Pacientes
Envelhecimento da Pele/efeitos dos fármacos
[Mh] Termos MeSH secundário: Inibidores da Liberação da Acetilcolina/administração & dosagem
Toxinas Botulínicas Tipo A/administração & dosagem
Técnicas Cosméticas/tendências
Músculos Faciais/efeitos dos fármacos
Seres Humanos
Injeções Intramusculares/instrumentação
Injeções Intramusculares/métodos
Injeções Intramusculares/normas
Guias de Prática Clínica como Assunto
[Pt] Tipo de publicação:JOURNAL ARTICLE; REVIEW
[Nm] Nome de substância:
0 (Acetylcholine Release Inhibitors); EC 3.4.24.69 (Botulinum Toxins, Type A); EC 3.4.24.69 (abobotulinumtoxinA)
[Em] Mês de entrada:1706
[Cu] Atualização por classe:170719
[Lr] Data última revisão:
170719
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170408
[St] Status:MEDLINE
[do] DOI:10.1093/asj/sjw285


  2 / 278 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28388717
[Au] Autor:Nestor M; Ablon G; Pickett A
[Ad] Endereço:Voluntary Associate Professor, Department of Dermatology and Cutaneous Surgery, Department of Surgery, Division of Plastic Surgery, University of Miami Leonard Miller School of Medicine, Miami, FL, USA.
[Ti] Título:Key Parameters for the Use of AbobotulinumtoxinA in Aesthetics: Onset and Duration.
[So] Source:Aesthet Surg J;37(suppl_1):S20-S31, 2017 05 01.
[Is] ISSN:1527-330X
[Cp] País de publicação:England
[La] Idioma:eng
[Ab] Resumo:Time to onset of response and duration of response are key measures of botulinum toxin efficacy that have a considerable influence on patient satisfaction with aesthetic treatment. However, there is no overall accepted definition of efficacy for aesthetic uses of botulinumtoxinA (BoNT-A). Mechanical methods of assessment do not lend themselves to clinical practice and clinicians rely instead on assessment scales such as the Frontalis Activity Measurement Standard, Frontalis Rating Scale, Wrinkle Severity Scale, and Subject Global Assessment Scale, but not all of these have been fully validated. Onset of activity is typically seen within 5 days of injection, but has also been recorded within 12 hours with abobotulinumtoxinA. Duration of effect is more variable, and is influenced by parameters such as muscle mass (including the effects of age and sex) and type of product used. Even when larger muscles are treated with higher doses of BoNT-A, the duration of effect is still shorter than that for smaller muscles. Muscle injection technique, including dilution of the toxin, the volume of solution injected, and the positioning of the injections, can also have an important influence on onset and duration of activity. Comparison of the efficacy of different forms of BoNT-A must be made with the full understanding that the dosing units are not equivalent. Range of equivalence studies for abobotulinumtoxinA (Azzalure; Ipsen Limited, Slough UK/Galderma, Lausanne CH/Dysport, Ipsen Biopharm Limited, Wrexham UK/Galderma LP, Fort Worth, TX) and onabotulinumtoxinA (Botox; Allergan, Parsippany, NJ) have been conducted, and results indicate that the number of units of abobotulinumtoxinA needs to be approximately twice as high as that of onabotulinumtoxinA to achieve the same effect. An appreciation of the potential influence of all of the parameters that influence onset and duration of activity of BoNT-A, along with a thorough understanding of the anatomy of the face and potency of doses, are essential to tailoring treatment to individual patient needs and expectations.
[Mh] Termos MeSH primário: Inibidores da Liberação da Acetilcolina/farmacologia
Toxinas Botulínicas Tipo A/farmacologia
Técnicas Cosméticas/normas
Músculos Faciais/efeitos dos fármacos
Envelhecimento da Pele/efeitos dos fármacos
[Mh] Termos MeSH secundário: Inibidores da Liberação da Acetilcolina/administração & dosagem
Inibidores da Liberação da Acetilcolina/farmacocinética
Fatores Etários
Toxinas Botulínicas Tipo A/administração & dosagem
Toxinas Botulínicas Tipo A/farmacocinética
Ensaios Clínicos como Assunto
Técnicas Cosméticas/tendências
Face/anatomia & histologia
Músculos Faciais/fisiologia
Seres Humanos
Injeções Intramusculares/métodos
Satisfação do Paciente
Guias de Prática Clínica como Assunto
Equivalência Terapêutica
Fatores de Tempo
Resultado do Tratamento
[Pt] Tipo de publicação:JOURNAL ARTICLE; REVIEW
[Nm] Nome de substância:
0 (Acetylcholine Release Inhibitors); E211KPY694 (onabotulinumtoxinA); EC 3.4.24.69 (Botulinum Toxins, Type A); EC 3.4.24.69 (abobotulinumtoxinA)
[Em] Mês de entrada:1706
[Cu] Atualização por classe:171116
[Lr] Data última revisão:
171116
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170408
[St] Status:MEDLINE
[do] DOI:10.1093/asj/sjw282


  3 / 278 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28385185
[Au] Autor:Oshima M; Deitiker P; Hastings-Ison T; Aoki KR; Graham HK; Atassi MZ
[Ad] Endereço:Department of Biochemistry and Molecular Biology, Baylor College of Medicine, Houston, TX 77030, USA.
[Ti] Título:Antibody responses to botulinum neurotoxin type A of toxin-treated spastic equinus children with cerebral palsy: A randomized clinical trial comparing two injection schedules.
[So] Source:J Neuroimmunol;306:31-39, 2017 May 15.
[Is] ISSN:1872-8421
[Cp] País de publicação:Netherlands
[La] Idioma:eng
[Ab] Resumo:We have conducted a 26-month-long comparative study involving young patients (2-6years old) with a clinical diagnosis of spastic equinus secondary to cerebral palsy who have been treated with BoNT/A (BOTOX®, Allergan) tri-annually or annually. Serum samples were obtained to determine the presence or absence of blocking antibodies (Abs) by a mouse protection assay (MPA) and levels of anti-BoNT/A Abs by radioimmune assay (RIA). HLA DQ alleles were typed using blood samples to determine the possible association of certain HLA type(s) with the disease or with the Ab status. Blocking Abs were detected in only two out of 18 serum samples of the tri-annual group, but none were found in 20 samples of the annual group. The MPA-positive serum samples gave in RIA significantly higher anti-BoNT/A Ab-binding levels than the MPA-negative samples. On the other hand, when two MPA-positive sample data were excluded, serum samples from tri-annual and annual groups showed similar anti-BoNT/A Ab levels. Linkage of the disorder with a particular HLA DQA1 and DQB1 allele types was not observed due to the small sample size. However, by combining results with other studies on BoNT/A-treated Caucasian patients with cervical dystonia (CD), we found that, among Caucasian patients treated with BoNT/A, DQA1*01:02 and DQB1*06:04 were higher in Ab-positive than in Ab-negative patients. The genetic linkage was on the threshold of corrected significance.
[Mh] Termos MeSH primário: Formação de Anticorpos/efeitos dos fármacos
Toxinas Botulínicas Tipo A/imunologia
Toxinas Botulínicas Tipo A/uso terapêutico
Paralisia Cerebral/tratamento farmacológico
Espasticidade Muscular/tratamento farmacológico
[Mh] Termos MeSH secundário: Inibidores da Liberação da Acetilcolina
Animais
Anticorpos Bloqueadores/imunologia
Paralisia Cerebral/sangue
Paralisia Cerebral/complicações
Criança
Pré-Escolar
Esquema de Medicação
Feminino
Cadeias alfa de HLA-DQ/genética
Cadeias beta de HLA-DQ/genética
Teste de Histocompatibilidade
Seres Humanos
Masculino
Espasticidade Muscular/sangue
Espasticidade Muscular/complicações
Farmacogenética
Radioimunoensaio
[Pt] Tipo de publicação:JOURNAL ARTICLE; RANDOMIZED CONTROLLED TRIAL
[Nm] Nome de substância:
0 (Acetylcholine Release Inhibitors); 0 (Antibodies, Blocking); 0 (HLA-DQ alpha-Chains); 0 (HLA-DQ beta-Chains); 0 (HLA-DQA1 antigen); E211KPY694 (onabotulinumtoxinA); EC 3.4.24.69 (Botulinum Toxins, Type A)
[Em] Mês de entrada:1708
[Cu] Atualização por classe:171116
[Lr] Data última revisão:
171116
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170408
[St] Status:MEDLINE


  4 / 278 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28226378
[Au] Autor:Zhou R; Pan B; Wang C; Wang D
[Ad] Endereço:Department of Plastic and Reconstructive Surgery, Shanghai Ninth People's Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, People's Republic of China.
[Ti] Título:Mandibular Rim Trilogy with Botulinum Toxin Injection: Reduction, Projection, and Lift.
[So] Source:Facial Plast Surg;33(1):102-108, 2017 Feb.
[Is] ISSN:1098-8793
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:"Onabotulinum toxin A (Botox) revolution" has brought the fundamental change in the facial rejuvenation as well as the concept of microinjection. The aesthetic standard tends to be the "globalization"; however, Asians have different aesthetic cultures and unique facial features compared with Caucasians. A new rejuvenation concept is proposed during our practice; the Asian face should preserve the original facial identity during Botox treatments. The lower face is treated with botulinum toxin to achieve a harmonious facial profile. Twenty young females ranging in age from 30 to 45 years consented and received the three-pronged procedure from March 2014 to April 2015; photography at baseline and follow-up visit were taken and analyzed. After posttreatment for 2 months, significant improvement was observed compared with the baseline. And the reduced masseter prominence and prominent chin were obtained, showing a favorable facial contour and harmonious appearance during the follow-up. The novel three-pronged approach to lower facial rejuvenation was aimed at the Asian characteristic of hypertrophic masseter, chin retrusion, and the facial sagging during the aging process. Botox treatment was a quite effective and safe strategy to improve the appearance and contour of the lower face in Asian patients.
[Mh] Termos MeSH primário: Inibidores da Liberação da Acetilcolina/administração & dosagem
Toxinas Botulínicas Tipo A/administração & dosagem
Técnicas Cosméticas
Face/anatomia & histologia
Músculos Faciais
[Mh] Termos MeSH secundário: Adulto
Grupo com Ancestrais do Continente Asiático
Feminino
Seres Humanos
Injeções Intramusculares
Mandíbula
Músculo Masseter
Meia-Idade
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Acetylcholine Release Inhibitors); E211KPY694 (onabotulinumtoxinA); EC 3.4.24.69 (Botulinum Toxins, Type A)
[Em] Mês de entrada:1710
[Cu] Atualização por classe:171116
[Lr] Data última revisão:
171116
[Sb] Subgrupo de revista:D
[Da] Data de entrada para processamento:170223
[St] Status:MEDLINE
[do] DOI:10.1055/s-0037-1600525


  5 / 278 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28213829
[Au] Autor:Aydinlar EI; Dikmen PY; Kosak S; Kocaman AS
[Ad] Endereço:Department of Neurology, Acibadem University School of Medicine, Içerenkoy, Kayisdagi Cd, 34752, Atasehir/Istanbul, Turkey. elif.aydinlar@acibadem.edu.tr.
[Ti] Título:OnabotulinumtoxinA effectiveness on chronic migraine, negative emotional states and sleep quality: a single-center prospective cohort study.
[So] Source:J Headache Pain;18(1):23, 2017 Dec.
[Is] ISSN:1129-2377
[Cp] País de publicação:Italy
[La] Idioma:eng
[Ab] Resumo:BACKGROUND: OnabotulinumtoxinA (OnabotA) is considered effective in in patients with chronic migraine (CM) who failed on traditional therapies. This study was designed to evaluate the effect of OnabotA injection series on migraine outcome, negative emotional states and sleep quality in patients with CM. METHODS: A total of 190 patients with CM (mean (SD) age: 39.3 (10.2) years; 87.9% were female) were included. Data on Pittsburgh sleep quality index (PSQI), headache frequency and severity, number of analgesics used, Migraine Disability Assessment Scale. (MIDAS) scores and Depression, Anxiety and Stress Scale (DASS-21) were evaluated at baseline (visit 1) and 4 consecutive follow up visits, each conducted after OnabotA injection series; at week 12 (visit 2), week 24 (visit 3), week 36 (visit 4) and week 48 (visit 5) to evaluate change from baseline to follow up. RESULTS: From baseline to visit 5, significant decrease was noted in least square (LS) mean headache frequency (from 19.5 to 8.4, p = 0.002), headache severity (from 8.1 to 6.1, p = 0.017), number of analgesics (from 26.9 to 10.4, p = 0.023) and MIDAS scores (from 67.3 to 18.5, p < 0.001). No significant change from baseline was noted in global PSOI and DASS-21 scores throughout the study. CONCLUSIONS: Our findings revealed that OnabotA therapy was associated with significant improvement in migraine outcome leading to decrease in headache frequency and severity, number of analgesics used and MIDAS scores. While no significant change was noted in overall sleep quality and prevalence of negative emotional states, patients without negative emotional states at baseline showed improved sleep quality throughout the study.
[Mh] Termos MeSH primário: Toxinas Botulínicas Tipo A/administração & dosagem
Emoções/efeitos dos fármacos
Transtornos de Enxaqueca/diagnóstico
Transtornos de Enxaqueca/tratamento farmacológico
Sono/efeitos dos fármacos
[Mh] Termos MeSH secundário: Inibidores da Liberação da Acetilcolina/administração & dosagem
Adulto
Doença Crônica
Estudos de Coortes
Emoções/fisiologia
Feminino
Seguimentos
Seres Humanos
Masculino
Meia-Idade
Transtornos de Enxaqueca/epidemiologia
Transtornos de Enxaqueca/psicologia
Prevalência
Estudos Prospectivos
Sono/fisiologia
Resultado do Tratamento
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Acetylcholine Release Inhibitors); E211KPY694 (onabotulinumtoxinA); EC 3.4.24.69 (Botulinum Toxins, Type A)
[Em] Mês de entrada:1704
[Cu] Atualização por classe:171116
[Lr] Data última revisão:
171116
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170219
[St] Status:MEDLINE
[do] DOI:10.1186/s10194-017-0723-4


  6 / 278 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
[PMID]:27926552
[Au] Autor:Stewart DB; Gaertner W; Glasgow S; Migaly J; Feingold D; Steele SR
[Ad] Endereço:Prepared on behalf of the Clinical Practice Guidelines Committee of the American Society of Colon and Rectal Surgeons.
[Ti] Título:Clinical Practice Guideline for the Management of Anal Fissures.
[So] Source:Dis Colon Rectum;60(1):7-14, 2017 Jan.
[Is] ISSN:1530-0358
[Cp] País de publicação:United States
[La] Idioma:eng
[Mh] Termos MeSH primário: Inibidores da Liberação da Acetilcolina/uso terapêutico
Canal Anal/cirurgia
Bloqueadores dos Canais de Cálcio/uso terapêutico
Procedimentos Cirúrgicos do Sistema Digestório/métodos
Fissura Anal/terapia
Doadores de Óxido Nítrico/uso terapêutico
[Mh] Termos MeSH secundário: Administração Tópica
Toxinas Botulínicas/uso terapêutico
Tratamento Conservador
Seres Humanos
[Pt] Tipo de publicação:JOURNAL ARTICLE; PRACTICE GUIDELINE
[Nm] Nome de substância:
0 (Acetylcholine Release Inhibitors); 0 (Calcium Channel Blockers); 0 (Nitric Oxide Donors); EC 3.4.24.69 (Botulinum Toxins)
[Em] Mês de entrada:1704
[Cu] Atualização por classe:170817
[Lr] Data última revisão:
170817
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:161208
[St] Status:MEDLINE


  7 / 278 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:27893541
[Au] Autor:Vadeboncoeur S; Richer V; Nantel-Battista M; Benohanian A
[Ad] Endereço:*All authors are affiliated with the Department of Medicine, Dermatology Division, Hôpital Saint-Luc du Centre Hospitalier de l'Université de Montréal, Montreal, Quebec.
[Ti] Título:Treatment of Palmar Hyperhidrosis With Needle Injection Versus Low-Pressure Needle-Free Jet Injection of OnabotulinumtoxinA: An Open-Label Prospective Study.
[So] Source:Dermatol Surg;43(2):264-269, 2017 Feb.
[Is] ISSN:1524-4725
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:BACKGROUND: OnabotulinumtoxinA (OnabotA) injections are effective to treat palmar hyperhidrosis (HH) but are quite painful. OBJECTIVE: To evaluate efficacy and pain of OnabotA injection using a needle-free jet apparatus compared with the traditional needle injection to treat palmar HH. METHODS: Twenty patients were recruited for a prospective open-label study. Their right hand was injected with 1% lidocaine with a jet injector, after which OnabotA was injected with a needle. The left hand was injected with OnabotA directly using the jet injector. Pain scores were recorded for both techniques. At 0, 1, 3, and 6 months, severity of palmar HH was evaluated with the Hyperhidrosis Disease Severity Scale (HDSS). RESULTS: One point reduction in the HDSS score at 1 month showed no statistical difference between both hands (p = .451). However, the HDSS score at 1 month from baseline dropped by 1.6 for the hand treated with traditional needle injection of OnabotA compared with 1.25 for the hand treated with jet injections (p = .031). There was no statistical difference in the pain on injection with both techniques (p = .1925). CONCLUSION: This study demonstrates effective and relatively painless use of a low-pressure jet injector for OnabotA in palmar HH.
[Mh] Termos MeSH primário: Inibidores da Liberação da Acetilcolina/administração & dosagem
Toxinas Botulínicas Tipo A/administração & dosagem
Dermatoses da Mão/tratamento farmacológico
Hiperidrose/tratamento farmacológico
[Mh] Termos MeSH secundário: Inibidores da Liberação da Acetilcolina/efeitos adversos
Adulto
Toxinas Botulínicas Tipo A/efeitos adversos
Feminino
Seres Humanos
Injeções a Jato
Masculino
Meia-Idade
Dor/prevenção & controle
Estudos Prospectivos
Resultado do Tratamento
Adulto Jovem
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Acetylcholine Release Inhibitors); E211KPY694 (onabotulinumtoxinA); EC 3.4.24.69 (Botulinum Toxins, Type A)
[Em] Mês de entrada:1704
[Cu] Atualização por classe:171116
[Lr] Data última revisão:
171116
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:161129
[St] Status:MEDLINE
[do] DOI:10.1097/DSS.0000000000000970


  8 / 278 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:27879418
[Au] Autor:Mosseri A; Cardona I; Blumenkrantz M; Daniel SJ
[Ad] Endereço:1 Department of Otolaryngology-Head and Neck Surgery, Montréal Children's Hospital, McGill University Health Center, Montréal, Canada.
[Ti] Título:Histopathologic Effects of Onabotulinum Toxin A Treatment in Pediatric Submandibular Glands.
[So] Source:Otolaryngol Head Neck Surg;156(2):368-370, 2017 Feb.
[Is] ISSN:1097-6817
[Cp] País de publicação:England
[La] Idioma:eng
[Ab] Resumo:Onabotulinum toxin A (OBTXA) is an effective treatment for drooling. Our objective was to determine if there are histologic changes in the submandibular glands (SMGs) after repetitive OBTXA injections. The study included blinded histologic analysis and comparison of SMGs with ≥4 OBTXA injections versus controls who never received OBTXA. The number of acinar cells were counted, and the morphology of the cells was evaluated within each histologic sample of the SMGs. Thirty-one glands were analyzed (14 control, 17 cases). No physical differences were observed between the 2 acinar cell groups. There was no significant difference in the number acinar cells per surface area in the control group as compared with the OBTXA group (1.29 ± 0.13 vs 1.17 ± 0.11 cells/µm , respectively). To conclude, no significant histologic findings were established in this first human study on SMGs post-OBTXA treatment.
[Mh] Termos MeSH primário: Inibidores da Liberação da Acetilcolina/uso terapêutico
Toxinas Botulínicas Tipo A/uso terapêutico
Sialorreia/tratamento farmacológico
Glândula Submandibular/efeitos dos fármacos
[Mh] Termos MeSH secundário: Criança
Feminino
Seres Humanos
Injeções
Masculino
Sialorreia/cirurgia
Resultado do Tratamento
[Pt] Tipo de publicação:COMPARATIVE STUDY; JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Acetylcholine Release Inhibitors); E211KPY694 (onabotulinumtoxinA); EC 3.4.24.69 (Botulinum Toxins, Type A)
[Em] Mês de entrada:1707
[Cu] Atualização por classe:171116
[Lr] Data última revisão:
171116
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:161124
[St] Status:MEDLINE
[do] DOI:10.1177/0194599816679940


  9 / 278 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:27862727
[Au] Autor:Zhu J; Ji X; Xu Y; Liu J; Miao YY; Zhang JA; Luo D; Zhou BR
[Ad] Endereço:Department of Dermatology, Affiliated Hospital of Nanjing University of TCM, Nanjing, Jiangsu, 210029, China.
[Ti] Título:The efficacy of intradermal injection of type A botulinum toxin for facial rejuvenation.
[So] Source:Dermatol Ther;30(1), 2017 Jan.
[Is] ISSN:1529-8019
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:The aim of this study is to evaluate the efficacy for effectiveness of type A botulinum toxin intradermal injection for facial rejuvenation. Forty female subjects were randomly divided into two groups: BoNTA group and control group. In BoNTA group, each subject's facial skin was treated with intradermal injection of BoNTA, and subjects of the control group were treated with intradermal saline solution injection. Subjects receiving one session of treatment and evaluations were conducted at baseline, four weeks, and twelve weeks after treatment. The outcome assessments included subjective satisfaction scale; blinded clinical assessment; and the biophysical parameters of roughness, elasticity, skin hydration, transepidermal water loss (TEWL), erythema, and melanin index. BoNTA group showed higher physician's global assessment score, subject satisfaction score, roughness, skin hydration, skin elasticity, and lower TEWL compared to that of control group at 12 weeks post-treatment. No significant difference was found among erythema and melanin index at baseline, four, and twelve weeks after treatment among the two major groups. In conclusion, intradermal BoNTA injection can be considered as an effective method for facial rejuvenation.
[Mh] Termos MeSH primário: Inibidores da Liberação da Acetilcolina/administração & dosagem
Toxinas Botulínicas Tipo A/administração & dosagem
Técnicas Cosméticas
Rejuvenescimento
Envelhecimento da Pele
[Mh] Termos MeSH secundário: Inibidores da Liberação da Acetilcolina/efeitos adversos
Adulto
Idoso
Toxinas Botulínicas Tipo A/efeitos adversos
China
Técnicas Cosméticas/efeitos adversos
Feminino
Seres Humanos
Injeções Intradérmicas
Meia-Idade
Satisfação do Paciente
Fotografia
Fatores de Tempo
Resultado do Tratamento
[Pt] Tipo de publicação:JOURNAL ARTICLE; RANDOMIZED CONTROLLED TRIAL
[Nm] Nome de substância:
0 (Acetylcholine Release Inhibitors); EC 3.4.24.69 (Botulinum Toxins, Type A)
[Em] Mês de entrada:1703
[Cu] Atualização por classe:170817
[Lr] Data última revisão:
170817
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:161119
[St] Status:MEDLINE
[do] DOI:10.1111/dth.12433


  10 / 278 MEDLINE  
              first record previous record
seleciona
para imprimir
Fotocópia
Chung, Tae Mo
Texto completo
[PMID]:27787630
[Au] Autor:Dressler D; Bhidayasiri R; Bohlega S; Chahidi A; Chung TM; Ebke M; Jacinto LJ; Kaji R; Koçer S; Kanovsky P; Micheli F; Orlova O; Paus S; Pirtosek Z; Relja M; Rosales RL; Sagástegui-Rodríguez JA; Schoenle PW; Shahidi GA; Timerbaeva S; Walter U; Saberi FA
[Ad] Endereço:Movement Disorders Section, Department of Neurology, Hannover Medical School, Carl-Neuberg-Str. 1, 30625, Hannover, Germany. dressler.dirk@mh-hannover.de.
[Ti] Título:Botulinum toxin therapy for treatment of spasticity in multiple sclerosis: review and recommendations of the IAB-Interdisciplinary Working Group for Movement Disorders task force.
[So] Source:J Neurol;264(1):112-120, 2017 Jan.
[Is] ISSN:1432-1459
[Cp] País de publicação:Germany
[La] Idioma:eng
[Ab] Resumo:Botulinum toxin (BT) therapy is an established treatment of spasticity due to stroke. For multiple sclerosis (MS) spasticity this is not the case. IAB-Interdisciplinary Working Group for Movement Disorders formed a task force to explore the use of BT therapy for treatment of MS spasticity. A formalised PubMed literature search produced 55 publications (3 randomised controlled trials, 3 interventional studies, 11 observational studies, 2 case studies, 35 reviews, 1 guideline) all unanimously favouring the use of BT therapy for MS spasticity. There is no reason to believe that BT should be less effective and safe in MS spasticity than it is in stroke spasticity. Recommendations include an update of the current prevalence of MS spasticity and its clinical features according to classifications used in movement disorders. Immunological data on MS patients already treated should be analysed with respect to frequencies of MS relapses and BT antibody formation. Registration authorities should expand registration of BT therapy for spasticity regardless of its aetiology. MS specialists should consider BT therapy for symptomatic treatment of spasticity.
[Mh] Termos MeSH primário: Inibidores da Liberação da Acetilcolina/uso terapêutico
Toxinas Botulínicas/uso terapêutico
Esclerose Múltipla/complicações
Espasticidade Muscular/tratamento farmacológico
Espasticidade Muscular/etiologia
[Mh] Termos MeSH secundário: Seres Humanos
Esclerose Múltipla/classificação
Esclerose Múltipla/tratamento farmacológico
Esclerose Múltipla/fisiopatologia
Espasticidade Muscular/classificação
Espasticidade Muscular/fisiopatologia
[Pt] Tipo de publicação:GUIDELINE; JOURNAL ARTICLE; REVIEW
[Nm] Nome de substância:
0 (Acetylcholine Release Inhibitors); EC 3.4.24.69 (Botulinum Toxins)
[Em] Mês de entrada:1704
[Cu] Atualização por classe:170928
[Lr] Data última revisão:
170928
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:161028
[St] Status:MEDLINE
[do] DOI:10.1007/s00415-016-8304-z



página 1 de 28 ir para página                         
   


Refinar a pesquisa
  Base de dados : MEDLINE Formulário avançado   

    Pesquisar no campo  
1  
2
3
 
           



Search engine: iAH v2.6 powered by WWWISIS

BIREME/OPAS/OMS - Centro Latino-Americano e do Caribe de Informação em Ciências da Saúde